Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept Provides Update on COVID-19 Testing with More than 50,000 Specimens Received
SAN DIEGO , Oct. 6, 2020 /PRNewswire/ --  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating patients with cancer, announces it has received more than 50,000 COVID-19 specimens to date for processing through its RT-PCR
View HTML
Toggle Summary Study Shows Biocept's Target Selector™ May Provide a More Robust Method for Detecting Lung Cancer Metastasis in Cerebrospinal Fluid than Cytology
SAN DIEGO   , Oct. 5, 2020 /PRNewswire/ --  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic tests and services for physicians treating cancer patients , announces results from a prospective study comparing its Target Selector™ cerebrospinal fluid testing to
View HTML
Toggle Summary Biocept to Present Study Results from Target Selector™ Testing in the Cerebrospinal Fluid of Patients with Lung Cancer at the IASLC Liquid Biopsy Meeting
SAN DIEGO , Oct. 1, 2020 /PRNewswire/ --  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic assays, products and services designed to provide physicians with clinically actionable information to improve patient outcomes, announces the upcoming presentation of
View HTML
Toggle Summary Biocept Announces the Award of Japanese Patent for Primer-Switch Mutation Detection and Amplification Improvement Platform Used to Detect Rare Cell Mutations in Tissue, Blood and Cerebrospinal Fluid
Further expands Company's patent portfolio in pursuit of worldwide intellectual property protection for Primer-Switch technology for the field of oncology SAN DIEGO , Sept. 23, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to
View HTML
Toggle Summary Biocept Announces that Highmark Has Made a Positive Coverage Determination on Target Selector™ Liquid Biopsy
Two-year evaluation in advanced lung cancers at Allegheny Health Network demonstrated improved access to optimal treatment while reducing healthcare costs SAN DIEGO , Sept. 21, 2020 /PRNewswire/ --  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to
View HTML
Toggle Summary Biocept Provides COVID-19 Testing Update with More than 35,000 Specimens Received
Announces distribution of approximately 83,000 specimen collection kits to clients SAN DIEGO , Sept. 16, 2020 /PRNewswire/ --  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve
View HTML
Toggle Summary Biocept to Present at the H.C. Wainwright Global Investment Virtual Conference on September 14
SAN DIEGO , Sept. 9, 2020 /PRNewswire/ --  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostics designed to provide physicians with clinically actionable information to improve the patient outcomes, announces that President and CEO Michael Nall will present at the
View HTML
Toggle Summary Biocept Executes In-Network Provider Agreement with Health Net Federal Services Extending Coverage for its Liquid Biopsy Oncology Platform to the TRICARE West Region Network
SAN DIEGO , Sept. 8, 2020 /PRNewswire/ --  Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve patient outcomes, announces it has entered into an agreement with Health Net Federal
View HTML
Toggle Summary Biocept Announces One-for-Ten Reverse Stock Split
SAN DIEGO , Sept. 4, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve patient outcomes, announces that, as a result of the Company's one-for-ten reverse stock
View HTML
Toggle Summary Biocept Provides COVID-19 Testing Update with More Than 21,000 COVID-19 Specimens Received and More than 20,000 Specimens Processed
Announces distribution of approximately 46,000 specimen collection kits to clients SAN DIEGO , Aug. 31, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve
View HTML